These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34768276)

  • 1. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine.
    Garakani A
    J Psychiatr Pract; 2021 Nov; 27(6):496-497. PubMed ID: 34768276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial.
    Jha MK; Wilkinson ST; Krishnan K; Collins KA; Sanacora G; Murrough J; Goes F; Altinay M; Aloysi A; Asghar-Ali A; Barnett B; Chang L; Costi S; Malone D; Nikayin S; Nissen SE; Ostroff R; Reti I; Wolski K; Wang D; Hu B; Mathew SJ; Anand A
    JAMA Netw Open; 2024 Jun; 7(6):e2417786. PubMed ID: 38916891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
    Mathew SJ; Wilkinson ST; Altinay M; Asghar-Ali A; Chang LC; Collins KA; Dale RM; Hu B; Krishnan K; Kellner CH; Malone DA; Murrough JW; Ostroff RB; Sanacora G; Shao M; Anand A
    Contemp Clin Trials; 2019 Feb; 77():19-26. PubMed ID: 30572160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.
    Tamman A; Anand A; Mathew SJ
    Expert Opin Drug Saf; 2022 Jun; 21(6):745-759. PubMed ID: 35253555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
    Ekstrand J; Fattah C; Persson M; Cheng T; Nordanskog P; Åkeson J; Tingström A; Lindström MB; Nordenskjöld A; Movahed Rad P
    Int J Neuropsychopharmacol; 2022 May; 25(5):339-349. PubMed ID: 35020871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Patient With Electroconvulsive Therapy-resistant Major Depressive Disorder With a Full Response to Heated Yoga: A Case Report.
    Sakurai H; Norton RJ; Fisher LB; Nagaswami MV; Streeter CC; Meyer AK; Dean T; Fava M; Mischoulon D; Nyer MB
    J Psychiatr Pract; 2021 Nov; 27(6):486-491. PubMed ID: 34768274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
    Anand A; Mathew SJ; Sanacora G; Murrough JW; Goes FS; Altinay M; Aloysi AS; Asghar-Ali AA; Barnett BS; Chang LC; Collins KA; Costi S; Iqbal S; Jha MK; Krishnan K; Malone DA; Nikayin S; Nissen SE; Ostroff RB; Reti IM; Wilkinson ST; Wolski K; Hu B
    N Engl J Med; 2023 Jun; 388(25):2315-2325. PubMed ID: 37224232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent Serotonin Syndrome After Ketamine-assisted Electroconvulsive Therapy: A Case Report and Review of the Literature.
    Deka A; Joseph E; Sharma N; Berhanu T; Kaplan J
    J Psychiatr Pract; 2024 May; 30(3):234-241. PubMed ID: 38819248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression.
    Zhong X; He H; Zhang C; Wang Z; Jiang M; Li Q; Zhang M; Huang X
    J Affect Disord; 2016 Sep; 201():124-30. PubMed ID: 27208499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial.
    Altinay M; Karne H; Anand A
    Psychopharmacol Bull; 2019 Feb; 49(1):8-16. PubMed ID: 30858635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonconvulsive Electrotherapy for Treatment Resistant Unipolar and Bipolar Major Depressive Disorder: A Proof-of-concept Trial.
    Regenold WT; Noorani RJ; Piez D; Patel P
    Brain Stimul; 2015; 8(5):855-61. PubMed ID: 26187603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations.
    Pompili M; Sarli G; Erbuto D; Manfredi G; Comparelli A
    Int Clin Psychopharmacol; 2023 May; 38(3):195-200. PubMed ID: 36630183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
    Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
    J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
    Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigström R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landén M; Lu Y
    Transl Psychiatry; 2023 Sep; 13(1):301. PubMed ID: 37770441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
    Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
    [No Abstract]   [Full Text] [Related]  

  • 18. The burden and the challenge of treatment-resistant depression.
    Touloumis C
    Psychiatriki; 2021 Dec; 32(Supplement I):11-14. PubMed ID: 34990376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: Intranasal esketamine for severe major depressive disorder with psychotic features.
    Carter M; Solsrud K; Mischel N
    Front Psychiatry; 2022; 13():937996. PubMed ID: 35958651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.